gemfibrozil has been researched along with fibrinogen in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (66.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avellone, G; Bompiani, GD; Cordova, R; De Simone, R; Di Garbo, V; Piliego, T; Raneli, G | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| de Valois, JC; Kastelein, JJ; Knipscheer, HC; van den Ende, B; Wouter ten Cate, J | 1 |
| Angelin, B; Bröijersén, A; Eriksson, M; Fatah, K; Goodall, AH; Hamsten, A; Hjemdahl, P; Silveira, A | 1 |
| Bode, C; Fujii, S; Kornas, K; Kübler, W; Nordt, TK; Peter, K; Sobel, BE | 1 |
| de Maat, MP; Kastelein, JJ; Kluft, C; Knipscheer, HC | 1 |
| de Maat, MP; Kastelein, JJ; Kluft, C; Knipscheer, HC; Kockx, M; Kooistra, T; Princen, HM | 1 |
| Rosenson, RS; Stein, JH | 1 |
| Arrol, S; Bhatnagar, D; Durrington, PN; Julier, K; Mackness, MI; Morgan, J; Prais, H; Wood, GN | 1 |
| Kockx, M; Kooistra, T; Princen, HM | 1 |
| Blazing, MA; Guyton, JR; Hagar, J; Kashyap, ML; Knopp, RH; McKenney, JM; Nash, DT; Nash, SD | 1 |
| Alfón, J; Badimon, L; Berrozpe, M; Royo, T | 1 |
| Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L | 1 |
| Chan, NN; Chow, FC | 1 |
| Brennan, SO; George, PM; Maghzal, GJ | 1 |
8 trial(s) available for gemfibrozil and fibrinogen
| Article | Year |
|---|---|
Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Double-Blind Method; Factor VII; Female; Fibrinogen; Fibrinolysis; Gemfibrozil; Humans; Hypertriglyceridemia; Lipoproteins; Male; Middle Aged; Plasminogen; Tissue Plasminogen Activator; Triglycerides | 1995 |
Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
Topics: Adult; Aged; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Retrospective Studies | 1996 |
Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
Topics: Adult; Aged; Analysis of Variance; Cross-Over Studies; Double-Blind Method; Factor VII; Factor VIIa; Factor XIIa; Fibrin; Fibrinogen; Gels; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Stress, Psychological; Thrombin | 1996 |
Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
Topics: Adult; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged | 1997 |
Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Smoking; Tissue Plasminogen Activator; Treatment Outcome | 1997 |
Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
Topics: Adult; Aged; Aryldialkylphosphatase; Bezafibrate; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Double-Blind Method; Esterases; Female; Fibrinogen; Gemfibrozil; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Plasminogen Activators | 1998 |
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Double-Blind Method; Female; Fibrinogen; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Triglycerides | 2000 |
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diet; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Triglycerides | 2001 |
7 other study(ies) available for gemfibrozil and fibrinogen
| Article | Year |
|---|---|
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors.
Topics: Fibrinogen; Gemfibrozil; Homeostasis; Humans; Insulin; Plasminogen Activator Inhibitor 1; Prodrugs; Proinsulin; Protein Precursors; Receptor, Insulin; RNA, Messenger; Tumor Cells, Cultured | 1997 |
Treatment of severe hypertriglyceridemia lowers plasma viscosity.
Topics: Adult; Aged; Aged, 80 and over; Blood Viscosity; Cholesterol; Cholesterol, HDL; Female; Fibrinogen; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Triglycerides | 1998 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia.
Topics: Animals; Antibodies; Aorta, Abdominal; Arteriosclerosis; Blood Platelets; Cholesterol; Disease Models, Animal; Fibrinogen; Fluorescent Antibody Technique; Gemfibrozil; Hyperlipidemias; Hypolipidemic Agents; Placebos; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Swine | 2000 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Fenofibrate; Fibrinogen; Gemfibrozil; Homocysteine; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2001 |
The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy.
Topics: Bezafibrate; Case-Control Studies; Female; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; N-Acetylneuraminic Acid; Pregnancy; Protein Subunits; Spectrometry, Mass, Electrospray Ionization; Thrombin Time | 2005 |